This report provides comprehensive information on the therapeutic development for Liver Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Liver Cirrhosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Liver Cirrhosis Overview
- Therapeutics Development
- Pipeline Products for Liver Cirrhosis - Overview
- Pipeline Products for Liver Cirrhosis - Comparative Analysis
- Liver Cirrhosis - Therapeutics under Development by Companies
- Liver Cirrhosis - Therapeutics under Investigation by Universities/Institutes
- Liver Cirrhosis Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Liver Cirrhosis - Products under Development by Companies
- Liver Cirrhosis - Products under Investigation by Universities/Institutes
- Liver Cirrhosis - Companies Involved in Therapeutics Development
- Conatus Pharmaceuticals Inc.
- Digna Biotech, S.L.
- Galectin Therapeutics, Inc.
- Gilead Sciences, Inc.
- GNI Group Ltd.
- Human Stem Cells Institute
- INVENT Pharmaceuticals, Inc.
- Nimbus Therapeutics, LLC
- Pacific Therapeutics Ltd.
- PharmaIN Corporation
- Pharmicell Co., Ltd.
- S-Evans Biosciences, Inc.
- Stelic Institute & Co., Inc.
- Stempeutics Research Private Limited
For more information visit http://www.researchandmarkets.com/research/wkkpjj/liver_cirrhosis